CN101861335B - 凝血因子viia调节剂的制造、组合物和用途 - Google Patents

凝血因子viia调节剂的制造、组合物和用途 Download PDF

Info

Publication number
CN101861335B
CN101861335B CN2008801165837A CN200880116583A CN101861335B CN 101861335 B CN101861335 B CN 101861335B CN 2008801165837 A CN2008801165837 A CN 2008801165837A CN 200880116583 A CN200880116583 A CN 200880116583A CN 101861335 B CN101861335 B CN 101861335B
Authority
CN
China
Prior art keywords
compound
composition
formula
cancer
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801165837A
Other languages
English (en)
Chinese (zh)
Other versions
CN101861335A (zh
Inventor
戴维·劳里
诺伯特·普罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of CN101861335A publication Critical patent/CN101861335A/zh
Application granted granted Critical
Publication of CN101861335B publication Critical patent/CN101861335B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801165837A 2007-10-16 2008-10-16 凝血因子viia调节剂的制造、组合物和用途 Active CN101861335B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98038607P 2007-10-16 2007-10-16
US60/980,386 2007-10-16
PCT/US2008/080221 WO2009052323A2 (en) 2007-10-16 2008-10-16 Manufacture, compositions and uses of coagulationfactor viia modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310334580.3A Division CN103705507A (zh) 2007-10-16 2008-10-16 凝血因子viia调节剂的制造、组合物和用途

Publications (2)

Publication Number Publication Date
CN101861335A CN101861335A (zh) 2010-10-13
CN101861335B true CN101861335B (zh) 2013-09-04

Family

ID=40568072

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310334580.3A Pending CN103705507A (zh) 2007-10-16 2008-10-16 凝血因子viia调节剂的制造、组合物和用途
CN2008801165837A Active CN101861335B (zh) 2007-10-16 2008-10-16 凝血因子viia调节剂的制造、组合物和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310334580.3A Pending CN103705507A (zh) 2007-10-16 2008-10-16 凝血因子viia调节剂的制造、组合物和用途

Country Status (9)

Country Link
US (3) US8552046B2 (enExample)
EP (2) EP2209801B1 (enExample)
JP (2) JP5733744B2 (enExample)
KR (1) KR20100093046A (enExample)
CN (2) CN103705507A (enExample)
CA (1) CA2702970A1 (enExample)
EA (2) EA201370191A1 (enExample)
ES (1) ES2403413T3 (enExample)
WO (1) WO2009052323A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2507707C (en) 2002-12-03 2011-06-21 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
CN1964951A (zh) 2004-06-02 2007-05-16 法莫西克立克斯公司 因子Ⅶa抑制剂
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
CA2702970A1 (en) 2007-10-16 2009-04-23 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulation factor viia modulator
WO2012142317A1 (en) * 2011-04-15 2012-10-18 Gamma Therapeutics, Inc Fast-clotting wound dressings
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
EA033469B1 (ru) 2012-04-16 2019-10-31 Cantab Biopharmaceuticals Patents Ltd Подкожное введение конъюгатов факторов крови с полиэтиленгликолем
EP3016646A4 (en) * 2013-07-05 2017-03-01 Shaker A. Mousa NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
MX391067B (es) * 2014-10-01 2025-03-21 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
RU2641058C1 (ru) * 2016-11-17 2018-01-15 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ профилактики венозной тромбоэмболии у больных раком шейки матки
CN109627218B (zh) * 2018-11-27 2022-03-29 深圳市龙华区中心医院 一种抗凝小分子化合物及其应用和包含其的药物
CN116283896B (zh) * 2022-09-07 2024-10-29 广东晨康生物科技有限公司 一种具有pd-l1抑制活性的联苯类化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745070A (zh) * 2002-12-03 2006-03-08 Axys药物公司 作为因子viia抑制剂的2－(2－羟基联苯－3－基)－1h－苯并咪唑－5－甲脒衍生物
CN1964951A (zh) * 2004-06-02 2007-05-16 法莫西克立克斯公司 因子Ⅶa抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
RU2093176C1 (ru) * 1992-12-16 1997-10-20 Левон Никитович Мкртчян Способ лечения рака молочной железы и рака тела матки
JP2002532479A (ja) 1998-12-18 2002-10-02 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼインヒビター
US20020037912A1 (en) 2000-08-11 2002-03-28 Leahy Ellen M. Factor viia inhibitors
US6465503B2 (en) 2000-08-11 2002-10-15 Axys Pharmaceuticals, Inc. Selective urokinase inhibitors
EP1449555B1 (en) * 2001-03-23 2006-06-21 Novo Nordisk A/S Needle cannula
US20030114457A1 (en) * 2001-07-09 2003-06-19 Axys Pharmaceuticals, Inc. 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
CA2474195A1 (en) * 2002-02-13 2003-08-21 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
KR20070087004A (ko) 2002-04-08 2007-08-27 엠쥐아이 쥐피, 아이엔씨. 프로포폴의 수용성 프로드럭을 함유하는 약제학적 조성물및 그것을 투여하는 방법
WO2004062661A1 (en) * 2003-01-08 2004-07-29 Axys Pharmaceuticals, Inc. 2-‘5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
EP1751114A2 (en) * 2004-06-02 2007-02-14 Pharmacyclics, Inc. Factor viia inhibitor
CA2702970A1 (en) 2007-10-16 2009-04-23 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulation factor viia modulator
US20110299806A1 (en) * 2010-06-08 2011-12-08 Leonid Kashchenevsky Spindle, shaft supporting device and method of supporting a rotatable shaft

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745070A (zh) * 2002-12-03 2006-03-08 Axys药物公司 作为因子viia抑制剂的2－(2－羟基联苯－3－基)－1h－苯并咪唑－5－甲脒衍生物
CN1964951A (zh) * 2004-06-02 2007-05-16 法莫西克立克斯公司 因子Ⅶa抑制剂

Also Published As

Publication number Publication date
US8552046B2 (en) 2013-10-08
EP2209801A4 (en) 2011-04-06
EP2209801A2 (en) 2010-07-28
US20100298396A1 (en) 2010-11-25
WO2009052323A2 (en) 2009-04-23
EA019258B1 (ru) 2014-02-28
EA201000633A1 (ru) 2011-04-29
JP2011500717A (ja) 2011-01-06
US8748468B2 (en) 2014-06-10
US20140039022A1 (en) 2014-02-06
JP2015157830A (ja) 2015-09-03
HK1147267A1 (en) 2011-08-05
US20130158089A1 (en) 2013-06-20
EP2209801B1 (en) 2013-01-16
CN103705507A (zh) 2014-04-09
CA2702970A1 (en) 2009-04-23
ES2403413T3 (es) 2013-05-17
EP2586794A2 (en) 2013-05-01
CN101861335A (zh) 2010-10-13
WO2009052323A3 (en) 2009-09-11
JP5733744B2 (ja) 2015-06-10
EA201370191A1 (ru) 2014-05-30
EP2586794A3 (en) 2013-07-17
KR20100093046A (ko) 2010-08-24

Similar Documents

Publication Publication Date Title
CN101861335B (zh) 凝血因子viia调节剂的制造、组合物和用途
US11304950B2 (en) Methods for treating testicular and ovarian adrenal rest tumors
US10570124B2 (en) Deoxycytidine kinase binding compounds
US20250269109A1 (en) Apparatus for and method in direct drug infusion using a label as a hanger
US20230277757A1 (en) Point of care drug delivery apparatus and method
TW202233613A (zh) 去氧胞苷激酶抑制劑之結晶型及其用途
HK1181783A (en) Manufacture, compositions and uses of coagulationfactor viia modulator
HK1147267B (en) Manufacture, compositions and uses of coagulationfactor viia modulator

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1147267

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1147267

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160720

Address after: California, USA

Patentee after: LES LABORATOIRES SERVIER

Address before: California, USA

Patentee before: PHARMACYCLICS, Inc.

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Illinois, USA

Patentee after: LES LABORATOIRES SERVIER

Country or region after: U.S.A.

Address before: California, USA

Patentee before: LES LABORATOIRES SERVIER

Country or region before: U.S.A.